The invention relates generally to the field of markers for medical detection and more specifically to magnetic medical markers.
With the increasing prevalence of mammography screening programs, the majority of breast cancers are detected as small, non-palpable (or occult) lesions that are amenable to breast conserving treatment. Accurate localization of non-palpable breast cancers is key to allowing surgical removal of the complete tumor with adequate margins. If the tumor is not completely excised, patients need to undergo a further operation to remove any remaining cancerous tissue. Accurate localization also helps to avoid excision of excess breast tissue that could result in adverse cosmetic results. Accurate localization is required by other cancers such as colorectal, prostate and lung, as well as other conditions known by those of ordinary skill in this art.
The current gold standard for localization of non-palpable lesions during surgery is wire-guided localization (WGL). Although this technique is widely used, WGL has a number of disadvantages. First, it involves two separate procedures, and can present logistical and scheduling difficulties between radiology and surgery departments. Second, the positioning of the guidewire may not be optimal for achieving the desired cosmetic result in the subsequent surgery. Third, the hook wire can migrate away from the site of the lesion or become displaced during mammography or moving the patient. Fourth, the insertion of the wire can be painful for patients and finally, the risk of infection means that surgery usually needs to take place the same day as the wire insertion.
In order to overcome these disadvantages, other localization techniques have been developed. One such technique is Radioguided Occult Lesion Localization (ROLL) using a radiotracer injected into the tumor and detected by a handheld gamma probe. Although this removes the logistical complexity of WGL, the technique introduces the drawback of the use of radioactive materials, which require special handling and disposal procedures.
Magnetic markers are also used, and they overcome the inconvenience and logistical challenges that arise by using a radioactive material as a marker, and they also avoid the drawbacks of guide-wires. However, magnetic markers are relatively complex to manufacture compared with guide-wires.
All known marking devices, including wire guides and magnetic markers, are introduced through a hollow needle or cannula. To minimize patient discomfort, this needle is typically narrow in diameter. The small diameter of the needle constrains the marker cross section. For conventional biopsy needles this dimension is generally 14 to 18 gauge. This means that the needle has an internal diameter generally of 0.8 mm to 1.5 mm but may possibly be as large as 1.8 mm for certain needle designs. If a vacuum-assisted needle is used, the needle size is typically 11 gauge, with an internal diameter of 2.3 to 2.5 mm. Thus, the magnetic markers are typically constrained to be less than 1.5 mm in diameter. In practice, these size constraints limit the magnetic response and in turn the ease with which the marker can be localised with a magnetic probe. Therefore, a stronger magnetic response is desired.
Another challenge for magnetic biopsy markers is that to achieve an effective magnetic response, the volume of material needs to be maximised. This volume requirement results in a typically shaped marker having a length significantly greater than its diameter. Such markers are in the region of 1 mm to 12 mm, with a length to diameter ratio greater than 5. This aspect ratio results in a non-uniform magnetic response with a much stronger signal being obtained when the marker major axis is in line with a probe, and a weaker signal when the marker major axis is transverse to the probe. A more uniform response is generally desired.
Further, the marker is generally guided to its position and confirmed to be in place under ultrasound or stereotactic x-ray imaging. This means that it is desirable for the marker to be clearly visible under X-ray and ultrasound imaging, and preferably under Mill, which can also be used for this purpose.
What is needed is a marker that has a small amount of material without reducing the intensity of the detectable signal, and provides a more uniform response from any direction relative to the magnetic probe.
The present invention addresses this need.
The invention relates to magnetic markers for surgical use. In particular, it relates to magnetic markers with a more uniform magnetic response once deployed than would be expected from their geometry prior to deployment.
In one aspect, markers are provided whose shape is chosen such that they give a more uniform magnetic response.
In another aspect, markers are provided whose geometrical configuration changes once deployed such that they give a more uniform magnetic response.
In another aspect, markers are provided whose material composition is chosen such that they give a more uniform magnetic response than would be expected from their geometry prior to deployment.
In one aspect, the marker is in a non-spherical configuration having a ratio of anisotropy of magnetic susceptibility of less than 9. In yet another embodiment, the marker is in a non-spherical configuration having a ratio of anisotropy of magnetic susceptibility of less than 6. In still yet another embodiment, the marker is in a non-spherical configuration having a ratio of anisotropy of magnetic susceptibility of less than 3. In one embodiment, the non-spherical marker configuration is of the shape selected from the group comprising a cylinder, a cable, a “dumbbell-like” form, a bead and a ball of yarn. In another embodiment, the cylinder bends upon placement in tissue. In yet another embodiment, the non-spherical configuration is faceted.
In one embodiment, the marker is a magnetic marker for marking a site in tissue in the body comprising: a plurality of magnetic components linked by flexible non-magnetic components that compact upon placement in the site. In another embodiment, the magnetic marker for marking a site in tissue in the body includes a magnetic component of a first shape located within a non-magnetic matrix of a second shape. In yet another embodiment, the magnetic marker for marking a site in tissue in the body includes a magnetic material core within a magnetic material sheath. In still another embodiment, one of the core and the sheath is a soft-magnetic material.
In one embodiment, the magnetic marker for marking a site in tissue in the body includes a plurality of magnetic components which self assemble into the magnetic marker following placement of the markers into the body. In another embodiment, the magnetic components are each encased within a super-hydrophobic coating. In still yet another embodiment, the magnetic marker for marking a site in tissue in the body includes a magnetic metallic glass.
The structure and function of the invention can be best understood from the description herein in conjunction with the accompanying figures. The figures are not necessarily to scale, emphasis instead generally being placed upon illustrative principles. The figures are to be considered illustrative in all aspects and are not intended to limit the invention, the scope of which is defined only by the claims.
A method for making magnetic markers as permanent magnets is described in U.S. Pat. No. 6,173,715. Permanent magnet implants have the drawback that they will attract any magnetic material in the vicinity and therefore could interact undesirably with other implants, or move in the tissue, for example, when a surgical tool made from magnetic material is nearby.
A method for making markers formed from superparamagnetic iron oxide (SPIO) nanoparticles in bioabsorbable form is described in US Publication No. 2014/0314679. SPIO particles avoid the concerns that occur for permanent magnetic markers because such materials have no magnetic remanence, and are not magnetic in themselves, but only become magnetized when in the presence of a magnetic field. The detection and localization of these SPIO magnetic markers can be performed with a sensitive magnetometer (or susceptometer) that generates an alternating magnetic field to excite the marker magnetically, and detects the magnetic field signature generated by the marker, as disclosed in US Publication No. 2011/0133730.
Another challenge for magnetic biopsy markers is that to achieve an effective magnetic response, the volume of material needs to be maximised. These requirements result in a typical marker having length significantly greater than the diameter because the marker must be delivered through a needle and smaller needle gauges (diameters) are less painful for patients. Such markers are in the region of 1 mm to 12 mm, with length to diameter ratio greater than 5. In practice, these size constraints limit the magnetic response and in turn the ease with which the marker can be localised with a magnetic probe. Therefore a stronger response is desired.
Further, the marker is generally guided to its position and confirmed to be in place under ultrasound or stereotactic x-ray imaging. This means that it is desirable for the marker to be clearly visible under X-ray and ultrasound imaging, and preferably under MRI, which can also be used for this purpose. SPIO particles have limited visibility under X-ray imaging but can be made ultrasound visible by combining them in a matrix of echogenic material, for example a polymer. Although magnetic markers overcome the drawbacks of guide-wires and radioactive approaches, there remains a need for a magnetic marker that can be introduced through a narrow needle, gives a strong magnetic response, is visible under X-ray and ultrasound imaging, and can be manufactured simply.
The requirement for the marker to be magnetically localisable requires a certain magnetic response from the implanted material, and for this response to be measurable at a distance removed from the material. This response is related to the magnetic susceptibility parameter. In SI units the magnetic susceptibility is a dimensionless proportionality constant that indicates the degree of magnetization induced in a material in response to an applied magnetic field, and is defined by:
M=H
Magnetic susceptibility can be measured by a range of known methods including the Faraday balance, Gouy balance, the magnetic resonance method, and the inductive method with SQUID magnetometer. Magnetic susceptibility can also be calculated using computer-based finite element magnetic modelling packages such as ANSYS Maxwell (ANSYS Inc., Canonsburg, PA), by modelling the marker in a homogenous field and measuring the distortions caused by the marker which correspond to the magnetic susceptibility. See for example the method described in: “Magnetic Susceptibility Modelling Using ANSYS”, K. Bartusek et al., Progress In Electromagnetics Research Symposium Proceedings, Marrakesh, Morocco, Mar. 20-23, 2011.
For a given material, a magnetic mass susceptibility can be defined which is the induced magnetic response per unit mass of the material. Magnetic mass susceptibility, ρ=k/ρ where p is the density of the material and ρ has units of m3/kg. This is a normalized susceptibility and allows the relative susceptibilities of different materials to be compared. For example, the magnetic mass susceptibility of 316 stainless steel, a standard material for biopsy markers, has a range of approximately is approximately 3.80×10−7 to 1.27×10−6, a permanent Neodymium magnet has a value approximately of 6.67×10−6, Super Paramagnetic Iron Oxide (SPIO) based markers have a value of approximately 2.5×10−5-1.0×10−3 depending on the density of particles in a matrix, while NiZn-ferrites have a range of approximately 3×10−3 to 1.22×10−1. Therefore, the NiZn-ferrites require less material to be detected than SPIO which in turn require less material than permanent Neodymium magnetic material or 316 stainless steel.
For a magnetically soft marker of volume V, subject to a field H in the linear susceptibility region, the total induced moment on the marker will be m=M V=V H. This moment will give rise to its own magnetic field Hmarker, which at a distance removed from the marker may be approximated as that due to an equivalent point dipole moment, namely:
where r is the unit vector. It is this induced field, Hmarker, that is measurable and which makes the magnetic marker localizable.
However, there are other factors that may affect the ease with which a given marker may be located—or in other words, affect the strength of the induced field, Hmarker, at a given r. One of these is known as ‘demagnetization’. This is a phenomenon that occurs in objects of finite size, where the induced field due to the magnetization in one part of the body acts to demagnetize another part of the same body. The effect is very complex to predict in other than the most simple geometries, and is therefore most often described, as here, for the special case of the object being an ellipsoid of revolution (e.g. a sphere, cylinder or disk). In such a case, the induced magnetization within the object is uniform, and the local magnetic field is commonly written:
Hlocal=H−Hdemag=H−N M
where Hdemag is the ‘demagnetisation field’ and N is the ‘demagnetisation factor’, although more accurately Hdemag should be defined along the x, y, z principal axes of the ellipsoid, as:
Hdemagx=NxMx,Hdemag=NyMy, and Hdemag=NzMz
In SI units Nx+Ny+Nz=1. For the case of a sphere, Nx=Ny=Nz=⅓. For the case of a long z-axis cylinder, Nx=Ny=½ and Nz=0. For the case of a thin xy-plane disk, Nx=Ny=0 and Nz=1. In the case of a marker made from a given single material of a given mass, the shape of that marker will affect the ease with which it may be localized.
For example: if the marker is made into a sphere, it will experience Hlocal=H−⅓M, irrespective of the orientation of the marker to the applied field. The induced moment will therefore be:
m=V Hlocal=VH−⅓m, or m=VH/(1+⅓)
The induced field, Hmarker, will therefore also be reduced by a factor of (1+⅓ ) at any given r, but this reduction will be present irrespective of the orientation of the marker to the magnetizing field H.
In contrast: if the marker were made into a cylinder, then if H was directed perpendicular to the long axis of the cylinder, then Hmarker would be reduced by a factor of (1+½ ), whereas if H was directed along the long axis, Hmarker would not be reduced at all. In this case the ratio ξ=(1+½ )/1 represents the anisotropic localization signal that the cylinder would present to any method dependent on the magnitude of Hmarker for its signal strength.
In the case of a cylinder of finite length, this ratio may be approximated as:
where N⊥=Nx=Ny, and N∥=Nz=1-2 N⊥. For example, in the case of the ferritic stainless steel samples listed in Table 2, for which is approximately 140, the measured ξ ratio of 10.3:1 for a cylinder of aspect ratio 7:1 corresponds to an N⊥ of approximately 0.48; while the same material in a cylinder of aspect ratio 3.7:1 exhibited an anisotropy ratio of approximately 4.7:1, corresponding to an N⊥ of approximately 0.44.
Thus, for a magnetic marker, the magnetic response depends partly on the mass susceptibility of its constituent material or materials, and partly on the shape of the marker, and for a given shape, the response can change with orientation of the marker. The anisotropy of the magnetic response can be calculated by using demagnetization factors as outlined above. However, as demagnetization factors are very difficult to calculate for real shapes, a more practical approach is needed to define the anisotropy of the response. The change in magnetic response with orientation for a given marker can be thought of as a change in the ‘effective susceptibility’ of the marker. The underlying susceptibility of the marker material does not change, but the change in magnetic response due to the combination of material, shape and orientation can be defined as if the susceptibility were varying.
Thus, for any given marker, a ratio can be defined of the maximum (effective) magnetic susceptibility to the minimum (effective) magnetic susceptibility. This ratio can be referred to as the anisotropy of the magnetic susceptibility and gives an indication of the uniformity of the magnetic susceptibility response along different axes of the marker or from different directions.
As magnetic susceptibility is dimensionless, the anisotropy of magnetic susceptibility, being a ratio of two dimensionless quantities, is also dimensionless. If the anisotropy is 1, the susceptibility is the same from any direction. If the anisotropy is high, the susceptibility is very non-uniform with respect to the orientation of the marker.
The concept of anisotropy of magnetic susceptibility is described in the art and can be measured by a number of methods. For example, two types of directional susceptibility meter are described in A. K. Dubey, “Understanding an Orogenic Belt”, Springer Geology: An equal-impedance bridge where the specimen can be inserted into a coil; and a balanced-transformer system where the specimen is placed inside a ferrite ring. A further method called a three dimensional magnetic anisotropic susceptibility meter is described in U.S. Pat. No. 3,492,566. In each case, a consistent magnetic field is applied to the sample, and the variation in the induced magnetic response is measured as the sample orientation is varied. A further such method is shown in
Measuring the anisotropy of magnetic susceptibility using a magnetic susceptibility probe or meter is the ideal approach to defining the uniformity of the magnetic response of a marker. However, there are alternative approaches to determining the level of anisotropy of magnetic susceptibility. For example, the projected area of the marker in any direction can be measured and maximum and minimum projected areas determined. For a given volume of marker material, a lower projected area indicates a greater focusing effect of the field and visa versa. As the focusing effect is inversely proportional to the projected area, the uniformity of response can thus be defined by the ratio of the minimum projected area to the maximum projected area of the marker out of all the available viewpoints or directions. This is the projected area anisotropy ratio of the magnetic marker, and provides a useful approximation to the anisotropy of magnetic susceptibility. A spherical marker would have a ratio of the minimum projected area to the maximum projected area=1. A rod shaped marker of diameter, d=0.75 and length, 1=7.5 would have a ratio of d×1/(pi×d2/4)=12.7.
It can also be seen that this ratio of projected areas is approximately equal to the shape factor of the marker, which is defined as the ratio of the largest dimension of the marker to its smallest dimension and this too can be used as an approximation to the anisotropy of magnetic susceptibility. Both these geometric methods do not account for variations in the magnetic properties within the marker.
Where the term ‘anisotropy of magnetic susceptibility’ or magnetic anisotropy is used throughout, the term ‘projected area anisotropy’ or ‘ratio of largest to smallest dimension’ are understood as alternative interchangeable measures of the uniformity of the magnetic response.
The anisotropy of magnetic susceptibility can be determined for the marker both before deployment when in the delivery device and after deployment. Where the marker configuration changes, the anisotropy of magnetic susceptibility may have a different value before and after deployment.
From a practical perspective, during surgery to detect the marker using a magnetic probe as described in WO2014/013235, high anisotropy is undesirable: the magnetic signal at a constant distance will vary depending on the orientation of the marker relative to the probe and make the marker appear to be closer when approaching from some orientations and further away from others. Minimising the anisotropy for the implanted marker improves the surgeons' ability to localise the marker by making it more intuitive and increases the surgeons' ability to remove a safe margin of tissue around a lesion. An anisotropy ratio of 1 is the ideal, giving a uniform response from any direction. However, in practice this is challenging to achieve within the geometric constraints of delivery through a small needle as outlined herein. An anisotropy ratio of less than 7 (i.e. between 1 and 7), preferably less than 5 and more preferably less than 3 is desirable. Because the magnetic response reduces with distance exponentially, an anisotropy ratio of less than 2 is close enough to the ideal for practical use.
An ideal magnetic marker becomes magnetized in the presence of a magnetic field and exhibits no permanent magnetic remanence (retained magnetisation) when the field is removed, or in other words, an ideal marker is magnetically soft, i.e. formed from magnetically soft material or behaving as if it is magnetically soft. Magnetically soft is here defined as having a magnetic coercivity, Hc, of less than or equal to 1000 Oe, or preferably less than or equal to 100 Oe or more preferably less than or equal to 50 Oe is desired in various embodiments. During detection, the marker is magnetised and follows the dotted curve shown in
It should be noted that permanent magnets are magnetically hard, having both a high magnetic remanence and a high magnetic coercivity (
The amount of material required to be implanted to make a magnetic marker detectable depends upon the magnetic susceptibility (v) of the material, more specifically the magnetic mass susceptibility (ρ=v/φ, which can be expressed as:
ρ=(μr−1)/ρ
where μr is the relative magnetic permeability and ρ is the material density.
The material used in the magnetic marker should have a relative permeability greater than 100, and preferably greater than 500. When specialist magnetic materials such as high purity iron or amorphous materials such as metallic glasses are used, relative permeability is greater than 1000 and preferably greater than 5000. The marker should have a high magnetic mass susceptibility, ρ. For conventional magnetic materials such as irons, steels and ferrites, ρ should be greater than or equal to 0.05 m3 kg−1, preferably greater than or equal to 0.1 m3 kg−1 and more preferably greater than or equal to 1 m3 kg−1. The use of specialist magnetic materials such as high purity iron or amorphous materials such as metallic glasses allows even higher magnetic mass susceptibilities, and ρ is preferably greater than 5 m3 kg−1 and more preferably greater than 10 m3 kg−1.
If material magnetic mass susceptibility is high enough, a spherical marker, which is capable of being deployed from the conventional needle described, would be capable of being magnetically localised and provide a perfectly isotropic signal. Table 1 shows mass susceptibilities for a number of magnetic materials.
(m3kg−1)
The detection and localization of these magnetic markers can be performed with a sensitive magnetometer (or susceptometer) which generates an alternating magnetic field, to excite the marker magnetically, and detects the magnetic field signature generated by the marker, as disclosed in US Publication No. 2011/0133730. The marker could also be detected by other techniques such as MRI, magnetic particle imaging, eddy current measurement, hall effect, or magnetotomography.
In one aspect of the invention, the marker comprises superparamagnetic particles. Superparamagnetic particles typically contain an iron oxide (magnetite and/or maghaemite) core surrounded by a biocompatible coating such as dextran, carboxydextran, other sugars, albumin, PEG, or biocompatible polymers. To exhibit superparamagnetic behaviour, the particles' magnetic cores need to be below a critical diameter, typically in the range 3-25 nm depending on the material and structure.
Iron oxide is the preferred material for the superparamagnetic core because of its low toxicity, but there are other materials which could form a superparamagnetic core. The material of the core should be one that is capable of being magnetically ordered. It may be a metal, such as cobalt, iron, or nickel; a metal alloy, rare earth and transition metal alloy, M-type or spinel ferrite containing aluminium, barium, bismuth, cerium, chromium, cobalt, copper, dysprosium, erbium, europium, gadolinium, holmium, iron, lanthanum, lutetium, manganese, molybdenum, neodymium, nickel, niobium, palladium, platinum, praseodymium, promethium, samarium, strontium, terbium, thulium, titanium, vanadium, ytterbium, and yttrium or a mixture thereof.
The core can also be formed by oxidising a combination of an iron(II) salt and another metal salt. The metal salts which are beneficial include salts of aluminium, barium, bismuth, cerium, chromium, cobalt, copper, dysprosium, erbium, europium, gadolinium, holmium, iron, lanthanum, lutetium, manganese, molybdenum, neodymium, nickel, niobium, palladium, platinum, praseodymium, promethium, samarium, strontium, terbium, thulium, titanium, vanadium, ytterbium, and yttrium.
In another aspect of the invention, the marker comprises a solid, magnetically soft material to provide a significantly increased magnetic response when being localised with a magnetic susceptometry probe. Markers produced from magnetically soft materials can include various paramagnetic, ferromagnetic and ferrimagnetic materials such as iron, nickel, cobalt and their alloys, electrical iron (including FM, consumet electrical iron), silicon-irons (including “A”, “A-FM”, “B”, “B-FM”, “C” variants) iron-phosphorous, nickel-iron (e.g. HyRa alloys, HyMu alloys, Hipernom, Parmalloy, Superalloy, Mu-metal), Heusler alloys, Fernico alloys (Iron-Nickel-Cobalt based alloys), Cunife alloys (Copper-Nickel-Iron based alloys), Alcomax alloys (Iron-Nickel-Aluminium-Cobalt-Copper based alloys) various stainless steels from the 300 series (e.g. 302, 304, 316), 400 series (e.g. 410, 416, 420, 430, 440, 446, 470) as well as specialist stainless steel alloys (e.g. chrome-iron alloys such as Chrome-Core® series (Carpenter Technology Corp, Wyomissing PA), martensitic stainless steels), ferrites such as MnZn-ferrites, NiZn-ferrites, MgZn-ferrites, Ba-ferrites, MnMgZn-ferrites, and MgZnCu-ferrites.
In a preferred aspect of the invention, the marker comprises a metallic glass with a very high magnetic mass susceptibility to provide a significantly improved magnetic response. Metallic glasses are also known as amorphous metal or bulk metallic glass and include Fe or Co based material such as those produced by Metglas Inc. (Conway, SC) or Neomax Materials Co. Ltd (Osaka, Japan); and magnetic carbon allotropes (e.g. fullerenes, highly oriented pyrolitic graphite, carbon nanofoams, nano-porous carbon). Examples of metallic glasses include but are not limited to: FINEMET, NANOPERM, HITPERM (all Hitachi Metals, Tokyo, Japan), METGLAS #2605, METGLAS #2826, METGLAS #2615, METGLAS #2714A, METGLAS #2605.
In order to ensure biocompatibility, these materials may be coated or contained within a biocompatible or inert material for example Bioglass, diamond-like-carbon (DLC), gold, hydroxyapatite, Iron, magnesium, nitinol, parylene, phosphorylcholine (PC) polymer, Poly-butyl methacrylate (PMBA) and polyethylenevinyl acetate (PEVA), polyethylene, PET, polytetraflouroethyleene (PTFE), PEBAX, PEEK, PEKK, platinum, silicone, titanium and the like.
Further a shaped material such as a spring steel or shape memory materials alloys such as Nitinol, and shape memory polymers such as PEO-PET coblock polymers and PEEK could also provide additional function of forming a specific shape on deployment if surrounding or surrounded by a magnetically soft material.
The magnetic material could further be held within a biocompatible matrix, such as collagen, gelatin and other cellulose base materials, Polyvinyl alcohol (PVA), Polyglyconate, polyester based materials (formed by homopolymerization or copolymerization of one or more of these monomers: glycolide, L-lactide and its isomers, ε-caprolactone, p-dioxanone and trimethylene carbonate (TMC). These may include homopolymers such as: Poly(L-lactide) Poly(DL-lactide), Poly(TMC), Polycaprolactone (PCL), Polyglycolide (PGA), Poly(glycolide-L-lactide) (PGL), or Poly(p-dioxanone) (PDS); or co-polymers such as: L-Lactide/DL-Lactide, L-lactide/Glycolide, L-lactide/Caprolactone, DL-Lactide/Glycolide, DL-Lactide/Caprolactone, Glycolide/Caprolactone, L-lactide/Glycolide/Caprolactone, DL-Lactide/Glycolide/Caprolactone, Poly(dioxinone co-trim ethylene carbonate-co-glycolide) Glykomer 631 (marketed as Biosyn®); or copolymers of these with PDS, hydrogels (from one or more monomers of Hydroxyethyl methacrylate, Hydroxyethoxyethyl methacrylate, Hydroxydiethoxyethyl methacrylate, Methoxyethyl methacrylate, Methoxyethoxyethyl methacrylate, Methoxydiethoxyethyl methacrylate, Ethylene glycol dimethacrylate, N-vinyl-2-pyrrolidone, N-isopropyl AAm, Vinyl acetate, Acrylic acid, MAA, N-(2-hydroxypropyl) methacrylamide, Ethylene glycol, PEG acrylate, PEG methacrylate, PEG diacrylate, PEG dimethacrylate).
In one aspect of the invention the implanted marker is made from a single magnetically soft material and the marker is shaped to reduce the anisotropy of the magnetic response. This anisotropy is defined as the ratio of the maximum magnetic response to the minimum magnetic response. The anisotropy arises in shapes with a long thin aspect ratio because magnetically soft materials focus any magnetic field lines running through them. The focusing effect depends on the amount of material in the direction of the field lines. Thus, a long thin shape when its long axis is aligned with the field focuses many more field lines through the material than when its long axis is perpendicular to the field lines. The result is that the magnetic response measured by a susceptometer is much larger in the direction of the long axis than in the direction of the short axis.
Table 2 shows anisotropy ratios for a number of cylinders of magnetic material of various sizes.
By altering the shape to influence the focussing effect, the anisotropy can be altered. For example, by creating a bend in the marker the anisotropy ratio for a given pre-deployment dimensional ratio can be reduced significantly (
In some cases, it may be advantageous for the marker to assume the shape only after it has been deployed so that it can be packed more efficiently into the deployment needle prior to deployment. An elastic material or a section of elastic material may be used to facilitate this.
Such shapes include, but are not limited to the following:
In one aspect of the invention, the implanted marker is made primarily from a magnetically soft material and the marker has a long thin aspect ratio prior to deployment but changes configuration after deployment to a shape with a low anisotropy of the magnetic susceptibility. Prior to deployment, the marker may have a length to diameter ratio or shape factor of greater than 5, and a ratio of magnetic anisotropy of susceptibility of greater than 5 or even greater than 7 or 9, such values resulting from the extended length of the marker prior to deployment and being beneficial to increase the volume of marker contained in the needle so as to maximize the magnetic response once deployed. After deployment, the ratio of magnetic anisotropy of susceptibility is less than 5 and preferably less than 3, and ideally 2 or less to provide a more uniform magnetic response.
In one aspect, the marker is elastically deformable or resiliently deformable such that it elastically or resiliently changes in shape and size from a packed or pre-deployment shape within the needle or deployment device with an associated shape factor, to a post-deployment shape and shape factor. The elasticity or resilience may, for example, derive from the use of an elastic or resilient material or from an elastic, resilient or deployable structure or combinations thereof. Preferably, the magnetic marker is elastically or resiliently deformable between a packed configuration having a higher anisotropy of magnetic susceptibility, and a deployed/unpacked configuration having a lower anisotropy of magnetic susceptibility. Alternatively, the magnetic marker is elastically or resiliently deformable between a packed configuration having a higher projected area anisotropy ratio, and a deployed/unpacked configuration having a lower projected area anisotropy ratio.
Preferably the deployed or delivered configuration of the marker has an anisotropy of magnetic susceptibility of less than 5, more preferably less than 3 and ideally less than 2 in order to give the most uniform detection signal; while prior to deployment within the delivery device, the marker in its packed configuration has an anisotropy of magnetic susceptibility of greater than 5 and more preferably greater than 7, in order to maximize the volume of material in the marker given the constrained diameter of the delivery device. By analogy, the marker in its packed configuration has a projected area anisotropy ratio of greater than 5 and more preferably greater than 7; but in a deployed/unpacked configuration has a projected area anisotropy ratio of less than 5, more preferably less than 3 and ideally less than 2. In order to achieve this configuration change, the marker requires a degree of resilience whereby one dimension (e.g., the diameter perpendicular to the main axis) of the marker changes by a factor of, at least, 1.5 times from its packed value to its deployed value. Preferably the deployed dimension is larger than the packed dimension by a factor of greater than 2 and more preferably greater than 3 in order to provide a shape factor (ratio of maximum dimension to minimum dimension) close to 1 or 2 on deployment, while still having sufficient material to be detected.
The magnetic marker in its packed configuration is packed within a delivery device prior to use. The delivery device needs to be able to deliver the marker through the skin to mark the tissue area of interest, for example a cancerous lesion. Suitable delivery devices include any needle- or cannula-based delivery system, typically comprising a needle and means to propel the marker through the end or out of the side of the needle such as a plunger or stylet. The needle is preferably 14 to 18 gauge. This means that the needle has an internal diameter generally of 0.8 mm to 1.5 mm but may possibly be as large as 1.8 mm for certain needle designs. Preferably it is between 1.0 and 1.5 mm in diameter. If a vacuum-assisted needle is used, the needle size is typically 11 gauge, with an internal diameter of 2.3 to 2.5 mm.
Markers that achieve the desired change in anisotropy of the magnetic susceptibility between their packed and unpacked configurations include, but are not limited to the following:
“ball of yarn” type forms (
“Chinese-lantern” forms (
Markers comprising a plurality of magnetically soft elements joined with hinges as shown in
Advantageously, the multiple facets also provide superior ultrasound response. It is desirable to have at least 3 elements to obtain a uniform response, and many more may be added, although for complexity the number is preferably less than 20 and more preferably less than 10. The hinged and other flexible or resiliently deformable forms may comprise a plurality of smaller magnetic units or components joined by non-magnetic flexible or resiliently deformable links such as plastic or shape memory materials. Combinations of these forms, e.g., bent wire made from multi-strand cable, are also included. As shown in
Markers comprising a plurality of elements joined with collapsible links between them such that on deployment the elements collapse together to form an amorphous region with a low ratio of magnetic anisotropy of susceptibility. The links can be formed from a string-like material such as suture or other polymer. Preferably, the magnetically soft elements are links in a chain that can collapse on itself after deployment.
Markers comprising a springy or resiliently deformable wire, or cylindrical shape prior to deployment that on deployment forms a structure or wireframe. Such structures may include a cylindrical coil, helix, conical coil, spherical coil, random ‘ball of yarn’, or a polyhedron such as a tetrahedron or part thereof.
Markers comprising a resiliently deformable looped or shaped coil spring that is compressed prior to deployment and expands upon deployment to a shape with a low ratio of magnetic anisotropy of susceptibility. For example, a coil spring shaped into a circle gives a surprisingly low ratio of magnetic anisotropy of susceptibility (
Markers comprising two or more elements connected by a link formed from an elastic or resiliently deformable or springy material such that the elements once deployed spring into a new configuration giving a low magnetic anisotropy of susceptibility.
A further benefit of the “ball of yarn” (
The above features can be combined to provide a marker with reduced anisotropy and improved imaging.
In a further aspect of the invention, the ratio of magnetic anisotropy of susceptibility of the implanted marker is modified by varying the magnetic properties of the magnetically soft material forming the marker along its length.
In another aspect of the invention, the reduction in magnetic anisotropy of susceptibility can be achieved through use of composite materials such as the formation of ferrite via sintering with two or more materials where at least one material is a soft material distributed to provide a less anisotropic response. Similar forms can be created, as previously mentioned, where multiple materials are used within the marker. One such embodiment is a single segmented marker with a constant cross section.
An additional benefit of this aspect of the invention is that the soft distribution or shape can be independent of the external form and cross sections which improve imaging visibility under ultrasound or X-ray can be created. Further examples of composite magnetic markers with decreased anisotropy include soft markers distributed on a collapsible stent-like structure specifically those that are self-expanding.
Additionally, in a cable or multi-wire strands (especially where twisted) embodiments include hollow versions where the individual wires are formed from different materials or formed from composite material, e.g., a core and a covering or sheath material where at least one or more of these are magnetically soft materials. A specific example of this is where the core or covering material is made from Nitinol or other shape memory material (including shape memory polymers) which is used to form the post deployment shape (
Shaped markers with hinges of plastic/pre-stressed/shape memory in multiple materials with different magnetic properties are shown in
In another aspect of the invention, a long thin marker is divided into a number of smaller markers. The multiple markers that are packed together prior to deployment have the same overall dimensions and material, and can be used to decrease the anisotropy relative to the overall dimensions of the material. For example, 3×2 mm long or 2×3 mm long or 6×1 mm long marker pieces have decreased anisotropy in comparison to 1×6 mm long marker of the same outer diameter. Surprisingly, this reduction in anisotropy occurs even when the segments align one behind each other in the same shape as an individual marker of the combined dimensions. (Table 3) For example, a single marker of dimension 5 mm in ferritic stainless steel gives an anisotropy ratio of 6.7. Two markers of the 3 mm markers in the same material give an anisotropy ratio of between 3.2 and 4.6 depending on relative orientations.
In a further specific example of this, a set of markers or magnetic particles produced from magnetically soft material can retain a small amount of magnetism. Once deployed into the patient, these magnetic particles can then self-assemble into an associated magnetic marker which possesses lower magnetic anisotropy of susceptibility. Multiple magnetically soft markers with a small magnetic remanence will self-assemble into an associated magnetic marker with a substantially uniform amount of material in every direction, thereby minimising anisotropy (
In a further example of this, magnetically soft markers or particles encased within hydrophobic surfaces (nano-texturing via lotus effect, silica nano-coatings, EnBio CoBlast PTFE, Hydroxyapitite, carbon nanotube coatings, precipitate calcium carbide & fatty acid coating with polymer latex, manganese oxide polystyrene or zinc oxide polystyrene nano-composites) or spheres will pull together (self-assemble) on deployment into the patient. To minimise surface energy, this embodiment will form a close-packed shape such as a sphere or ellipsoid system which will have an improved magnetic anisotropy of susceptibility relative to the particles within the delivery system which will constrain in an elongated shape to be elongated.
In another aspect of the invention, small micromarkers or microparticles of a soft material can be suspended within a biocompatible matrix (
In a further example of this for the case, by using a gel matrix with a suspension of magnetically soft particles and by sizing these particles appropriately, the gel and particles can be deployed through the deployment needle (
The present invention provides various ways of making magnetic markers with acceptable anisotropy while not affecting the ease of delivery of the particles.
In another aspect of the invention, a method is provided for marking a soft tissue site of interest, such as the site of a tumor or benign lesion for example within the breast, lung, bowel/colon, rectum, prostate or other cancer affected organ, or a lymph node within the axilla or other nodal basin within the body. The method includes the steps of (i) inserting such a magnetic marker into tissue near the target lesion or site, and (ii) detecting such a marker using a susceptometer, and optionally (iii) surgically excising the target tissue around the marker. Preferably, the susceptometer detects the marker by providing a magnetic field in the region of the marker and measuring the induced magnetization in the marker.
Unless otherwise indicated, all numbers expressing lengths, widths, depths, or other dimensions, and so forth used in the specification and claims are to be understood in all instances as indicating both the exact values as shown and as being modified by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Any specific value may vary by 20%.
The terms “a,” “an,” “the,” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of any claim. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
Certain embodiments are described herein, including the best mode known to the inventor for carrying out the spirit of the present disclosure. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventor intends for the invention to be practiced otherwise than specifically described herein. Accordingly, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is contemplated unless otherwise indicated herein or otherwise clearly contradicted by context.
In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein. Accordingly, the claims are not limited to embodiments precisely as shown and described.
This application is a continuation of U.S. patent application Ser. No. 16/688,318 filed on Nov. 19, 2019, which is a continuation of U.S. patent application Ser. No. 15/172,187, filed on Jun. 3, 2016, now U.S. Pat. No. 10,595,957, which claims priority to and the benefit of U.S. Provisional Application No. 62/170,768, filed on Jun. 4, 2015, the entire disclosures of which are herein incorporated by reference herein. This application is a continuation of U.S. patent application Ser. No. 15/172,187, filed on Jun. 3, 2016, which claims priority to and the benefit of U.S. Provisional Application No. 62/170,768, filed on Jun. 4, 2015, the entire disclosures of which are herein incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
2614164 | Huston | Oct 1952 | A |
3445928 | Beynon | May 1969 | A |
3449662 | Wood | Jun 1969 | A |
3492566 | Gross | Jan 1970 | A |
4324255 | Branch et al. | Apr 1982 | A |
4823113 | Hasegawa | Apr 1989 | A |
4825162 | Roemer et al. | Apr 1989 | A |
4983912 | Roehrlein et al. | Jan 1991 | A |
5005001 | Cordery | Apr 1991 | A |
5055288 | Lewis et al. | Oct 1991 | A |
5184070 | Besendorfer et al. | Feb 1993 | A |
5261403 | Saito et al. | Nov 1993 | A |
5293119 | Podney | Mar 1994 | A |
5313192 | Ho | May 1994 | A |
5363845 | Chowdhury et al. | Nov 1994 | A |
5402094 | Enge | Mar 1995 | A |
5414356 | Yoshimura et al. | May 1995 | A |
5416413 | Leussler | May 1995 | A |
5437280 | Hussman | Aug 1995 | A |
5512821 | Ando et al. | Apr 1996 | A |
5534778 | Loos et al. | Jul 1996 | A |
5537037 | Otaka et al. | Jul 1996 | A |
5657756 | Vrba et al. | Aug 1997 | A |
5666052 | Sata | Sep 1997 | A |
5766572 | Hasegawa et al. | Jun 1998 | A |
5844140 | Seale | Dec 1998 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5997473 | Taniguchi et al. | Dec 1999 | A |
6076008 | Bucholz | Jun 2000 | A |
6082366 | Andrä et al. | Jul 2000 | A |
6173715 | Sinanan et al. | Jan 2001 | B1 |
6205352 | Carroll | Mar 2001 | B1 |
6230038 | von Gutfeld et al. | May 2001 | B1 |
6270464 | Fulton, III et al. | Aug 2001 | B1 |
6292678 | Hall | Sep 2001 | B1 |
6304075 | Cordery | Oct 2001 | B1 |
6347241 | Burbank et al. | Feb 2002 | B2 |
6352682 | Leavitt et al. | Mar 2002 | B2 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6394965 | Klein | May 2002 | B1 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6418335 | Avrin et al. | Jul 2002 | B2 |
6419847 | Toyota | Jul 2002 | B1 |
6427081 | Burbank et al. | Jul 2002 | B1 |
6445185 | Damadian et al. | Sep 2002 | B1 |
6549800 | Atalar et al. | Apr 2003 | B1 |
6592608 | Fisher et al. | Jul 2003 | B2 |
6603308 | Itozaki et al. | Aug 2003 | B2 |
6614084 | Cowburn | Sep 2003 | B1 |
6638913 | Speck et al. | Oct 2003 | B1 |
6662040 | Henrichs et al. | Dec 2003 | B1 |
6662041 | Burbank et al. | Dec 2003 | B2 |
6699205 | Fulton, III et al. | Mar 2004 | B2 |
6725083 | Burbank et al. | Apr 2004 | B1 |
6730042 | Fulton et al. | May 2004 | B2 |
6766186 | Hoyns et al. | Jul 2004 | B1 |
6815949 | Kandori et al. | Nov 2004 | B2 |
6835572 | Mountford et al. | Dec 2004 | B1 |
6850065 | Fujita et al. | Feb 2005 | B1 |
6862470 | Burbank et al. | Mar 2005 | B2 |
6889073 | Lampman et al. | May 2005 | B2 |
6920346 | Kazandjian et al. | Jul 2005 | B2 |
6949926 | Murakami et al. | Sep 2005 | B2 |
6963769 | Balaban et al. | Nov 2005 | B1 |
6996433 | Burbank et al. | Feb 2006 | B2 |
7009398 | Hahn et al. | Mar 2006 | B2 |
7044957 | Foerster et al. | May 2006 | B2 |
7084631 | Qu et al. | Aug 2006 | B2 |
7116094 | Levin et al. | Oct 2006 | B2 |
7229417 | Foerster et al. | Jun 2007 | B2 |
7283868 | Ko et al. | Oct 2007 | B2 |
7329414 | Fisher et al. | Feb 2008 | B2 |
7335511 | Mountford et al. | Feb 2008 | B2 |
7386338 | Hoppel et al. | Jun 2008 | B2 |
7412275 | Marinelli | Aug 2008 | B2 |
7416533 | Gellman et al. | Aug 2008 | B2 |
7479784 | Lee | Jan 2009 | B2 |
7525308 | Tsukuda et al. | Apr 2009 | B2 |
7535363 | Gisselberg et al. | May 2009 | B2 |
7570056 | Nakabayashi et al. | Aug 2009 | B2 |
7625397 | Foerster et al. | Dec 2009 | B2 |
7668582 | Sirimanne et al. | Feb 2010 | B2 |
7676256 | Satragno et al. | Mar 2010 | B2 |
7680524 | Ogawa et al. | Mar 2010 | B2 |
7689267 | Prince | Mar 2010 | B2 |
7701209 | Green | Apr 2010 | B1 |
7702378 | Bolan et al. | Apr 2010 | B2 |
7711407 | Hughes et al. | May 2010 | B2 |
7744852 | Chernomorsky et al. | Jun 2010 | B2 |
7776310 | Kaplan | Aug 2010 | B2 |
7783336 | Macfarlane et al. | Aug 2010 | B2 |
7792569 | Burbank et al. | Sep 2010 | B2 |
7877133 | Burbank et al. | Jan 2011 | B2 |
7970454 | Jones et al. | Jun 2011 | B2 |
7972619 | Fisher | Jul 2011 | B2 |
7983734 | Jones et al. | Jul 2011 | B2 |
8050742 | Weizman | Nov 2011 | B2 |
8060183 | Leopold et al. | Nov 2011 | B2 |
8062215 | Voegele et al. | Nov 2011 | B2 |
8064987 | Carr, Jr. | Nov 2011 | B2 |
8118754 | Flynn et al. | Feb 2012 | B1 |
8137320 | Mark et al. | Mar 2012 | B2 |
8174259 | Hattersley et al. | May 2012 | B2 |
8219182 | Burbank et al. | Jul 2012 | B2 |
8277391 | Foerster et al. | Oct 2012 | B2 |
8280486 | Miller et al. | Oct 2012 | B2 |
8292822 | Fulton et al. | Oct 2012 | B2 |
8306602 | Sirimanne et al. | Nov 2012 | B2 |
8320993 | Sirimanne et al. | Nov 2012 | B2 |
8320994 | Sirimanne et al. | Nov 2012 | B2 |
8452375 | Krag et al. | May 2013 | B2 |
8470294 | Kaplan | Jun 2013 | B2 |
8600481 | Sirimanne et al. | Dec 2013 | B2 |
8626269 | Jones et al. | Jan 2014 | B2 |
8718745 | Burbank et al. | May 2014 | B2 |
8821835 | Kaplan | Sep 2014 | B2 |
8880154 | Jones et al. | Nov 2014 | B2 |
20010006616 | Leavitt et al. | Jul 2001 | A1 |
20010011155 | Rapoport | Aug 2001 | A1 |
20010012915 | Avrin et al. | Aug 2001 | A1 |
20010049481 | Fulton, III et al. | Dec 2001 | A1 |
20020019595 | Osborne et al. | Feb 2002 | A1 |
20020035324 | Sirimanne et al. | Mar 2002 | A1 |
20020058883 | Fulton et al. | May 2002 | A1 |
20020107437 | Sirimanne et al. | Aug 2002 | A1 |
20020161298 | Burbank et al. | Oct 2002 | A1 |
20030016010 | Kandori et al. | Jan 2003 | A1 |
20030078493 | Ogawa et al. | Apr 2003 | A1 |
20030105394 | Fabian et al. | Jun 2003 | A1 |
20030141868 | Bajharev | Jul 2003 | A1 |
20030192557 | Krag et al. | Oct 2003 | A1 |
20030214313 | Omura et al. | Nov 2003 | A1 |
20030216632 | McClure et al. | Nov 2003 | A1 |
20040109823 | Kaplan | Jun 2004 | A1 |
20040138552 | Harel | Jul 2004 | A1 |
20040138555 | Krag et al. | Jul 2004 | A1 |
20040162477 | Okamura et al. | Aug 2004 | A1 |
20040204660 | Fulton et al. | Oct 2004 | A1 |
20040210160 | Fulton et al. | Oct 2004 | A1 |
20040236212 | Jones et al. | Nov 2004 | A1 |
20040236213 | Jones et al. | Nov 2004 | A1 |
20040249261 | Torchia et al. | Dec 2004 | A1 |
20050033157 | Klein et al. | Feb 2005 | A1 |
20050033195 | Fulton, III et al. | Feb 2005 | A1 |
20050045192 | Fulton et al. | Mar 2005 | A1 |
20050059881 | Balaban et al. | Mar 2005 | A1 |
20050059888 | Sirimanne et al. | Mar 2005 | A1 |
20050080337 | Sirimanne et al. | Apr 2005 | A1 |
20050080338 | Sirimanne et al. | Apr 2005 | A1 |
20050080339 | Sirimanne et al. | Apr 2005 | A1 |
20050085724 | Sirimanne et al. | Apr 2005 | A1 |
20050148863 | Okamura et al. | Jul 2005 | A1 |
20060036159 | Sirimanne et al. | Feb 2006 | A1 |
20060074295 | Kucharczyk et al. | Apr 2006 | A1 |
20060079770 | Sirimanne et al. | Apr 2006 | A1 |
20060079805 | Miller et al. | Apr 2006 | A1 |
20060079829 | Fulton et al. | Apr 2006 | A1 |
20060173283 | Axelsson et al. | Aug 2006 | A1 |
20060258933 | Ellis et al. | Nov 2006 | A1 |
20060270930 | Brasile | Nov 2006 | A1 |
20060293581 | Plewes et al. | Dec 2006 | A1 |
20070082021 | Bates | Apr 2007 | A1 |
20070093726 | Leopold | Apr 2007 | A1 |
20080074109 | Tsukada et al. | Mar 2008 | A1 |
20080091120 | Fisher | Apr 2008 | A1 |
20080097199 | Mullen | Apr 2008 | A1 |
20080124281 | Gao | May 2008 | A1 |
20080146914 | Polzin et al. | Jun 2008 | A1 |
20080161848 | Fisher | Jul 2008 | A1 |
20080214930 | Brasile | Sep 2008 | A1 |
20080228164 | Nicoson et al. | Sep 2008 | A1 |
20080275333 | Fain et al. | Nov 2008 | A1 |
20080294036 | Hoi et al. | Nov 2008 | A1 |
20090018439 | Jones et al. | Jan 2009 | A1 |
20090024022 | Azar et al. | Jan 2009 | A1 |
20090082662 | Israel | Mar 2009 | A1 |
20090118611 | He | May 2009 | A1 |
20090164161 | Hong et al. | Jun 2009 | A1 |
20090201016 | Hattersley et al. | Aug 2009 | A1 |
20100030149 | Carr, Jr. | Feb 2010 | A1 |
20100099978 | Geppert et al. | Apr 2010 | A1 |
20100125191 | Sahin | May 2010 | A1 |
20100261946 | Kaplan | Oct 2010 | A1 |
20100298698 | Burbank et al. | Nov 2010 | A1 |
20100305430 | Troesken | Dec 2010 | A1 |
20110021888 | Sing et al. | Jan 2011 | A1 |
20110052393 | Ogrin | Mar 2011 | A1 |
20110054519 | Neuss | Mar 2011 | A1 |
20110133730 | Hattersley | Jun 2011 | A1 |
20110137154 | Hattersley et al. | Jun 2011 | A1 |
20110237943 | Jones et al. | Sep 2011 | A1 |
20120229130 | Hattersley et al. | Sep 2012 | A1 |
20120330153 | Sirimanne et al. | Dec 2012 | A1 |
20130066195 | Sirimanne et al. | Mar 2013 | A1 |
20130253550 | Beisel et al. | Sep 2013 | A1 |
20130280168 | Kaplan | Oct 2013 | A1 |
20130310686 | Jones et al. | Nov 2013 | A1 |
20140018663 | Harmer et al. | Jan 2014 | A1 |
20140051996 | Sirimanne et al. | Feb 2014 | A1 |
20140194741 | Sirimanne et al. | Jul 2014 | A1 |
20140314679 | Shawcross et al. | Oct 2014 | A1 |
20150010470 | Kaplan | Jan 2015 | A1 |
20150051477 | Jones et al. | Feb 2015 | A1 |
20150078535 | DeSena et al. | Mar 2015 | A1 |
20150238661 | Kaplan | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
101087556 | Dec 2007 | CN |
101087558 | Dec 2007 | CN |
104105456 | Oct 2014 | CN |
29724862 | Mar 2005 | DE |
102007009016 | Aug 2008 | DE |
102011081445 | Feb 2013 | DE |
0126580 | Nov 1984 | EP |
0595227 | May 1994 | EP |
0663599 | Jul 1995 | EP |
0948940 | Oct 1999 | EP |
1249207 | Oct 2002 | EP |
0966924 | Aug 2003 | EP |
1062911 | Aug 2003 | EP |
1284123 | Jul 2005 | EP |
1491147 | Mar 2010 | EP |
2267471 | Dec 2010 | EP |
2339343 | Jun 2011 | EP |
2689638 | Oct 1993 | FR |
2770779 | May 1999 | FR |
2109112 | May 1983 | GB |
2425610 | Jan 2006 | GB |
2465771 | Jun 2010 | GB |
02-078983 | Nov 1990 | JP |
02-281170 | Nov 1990 | JP |
05-251774 | Sep 1993 | JP |
06-324021 | Nov 1994 | JP |
08-015229 | Jan 1996 | JP |
08-248004 | Sep 1996 | JP |
08-338864 | Dec 1996 | JP |
10-038854 | Feb 1998 | JP |
2002-004118 | Jan 2002 | JP |
2003-149212 | May 2003 | JP |
2005-168678 | Jun 2005 | JP |
2006-030004 | Feb 2006 | JP |
2012-177691 | Sep 2012 | JP |
09-027057 | Aug 2014 | JP |
2013-085642 | May 2023 | JP |
1995004287 | Feb 1995 | WO |
9807052 | Feb 1998 | WO |
200038579 | Jul 2000 | WO |
0108578 | Feb 2002 | WO |
0239917 | May 2002 | WO |
2002039917 | May 2002 | WO |
2005011512 | Feb 2005 | WO |
2006009048 | Jan 2006 | WO |
2006022786 | Mar 2006 | WO |
2006067664 | Jun 2006 | WO |
2006067692 | Jun 2006 | WO |
2006056739 | Jun 2006 | WO |
2006117530 | Nov 2006 | WO |
2007034196 | Mar 2007 | WO |
2007053533 | May 2007 | WO |
2011033306 | Mar 2011 | WO |
2011067576 | Jun 2011 | WO |
2013114247 | Aug 2013 | WO |
2014013235 | Jan 2014 | WO |
Entry |
---|
Anonymous: “Coercivity—Wikipedia”, Jul. 8, 2015 (Jul. 8, 2015), XP055334649, Retrieved from the Internet: URL: https://en.wikipedia.org/w/index.php?t itle=Coercivity&oldid=670537509 [retrieved on Jan. 12, 2017]. |
Anonymous: “Magnetic susceptibility—Wikipedia”, Dec. 8, 2022 (Dec. 8, 2022), XP093006269, Retrieved from the Internet: URL:https://en.wikipedia.org/wiki/Magnetic _susceptibility [retrieved on Dec. 8, 2022] (5 pages). |
Vazquez, M., et al., “A Soft Magnetic Wire for Sensor Applications”, Journal of Physics D: Applied Physics, Institute of Physics Publishing, Bristol, GB, vol. 29, No. 4, Apr. 14, 1996 (Apr. 14, 1996), pp. 939-949. |
Reedlunn, Benjamin, et al., “Superelastic shape memory alloy cables: Part I—Isothermal tension experiments”, International Journal of Solids and Structures, Feb. 28, 2013 vol. 50, No. 20-21, Oct. 1, 2013 (Oct. 1, 2013), pp. 3009-3026. |
European Search Report for Application No./Patent No. 22176363.4-1122 / 4085866 dated Dec. 13, 2022 (18 pages). |
English translation of Office Action for Japanese Patent Application No. 2008-508306, dispatched in Nov. 8, 2011, 6 pages. |
Freitas, Jr., “Nanomedicine, Volume I: Basic Capabilities”, www.nanomedicine.com/NMI/8.2.1.2.htm, Landes Bioscience, Georgetown, TX, 1999, 4 pages. |
Reddy et al., “Preparation & Application of Magnetic hydrogel nanocomposites for protein purification and Metal Absorption”, International Conference on Advances in Polymer Technology, Feb. 26-27, 2010, pp. 83-97, India. |
European Search Report for EP 10180206, Nov. 23, 2010, 4 pages. |
Fagaly, “Squid Detection of Electronic Circuits”, IEEE Transactions on Magnetics, vol. 25, No. 2, Mar. 1989; pp. 1216-1218. |
Noguchi et al., “Sentinel Lymphadenectomy in Breast Cancer. Identification of Sentinel Lymph Node and Detection of Metastases”, Breast Cancer Research and Treatment, vol. 53, 1999, pp. 97-104. |
Kim et al., “Near Infrared Fluorescent Type II Quantum Dots for Sentinel Lymph Node Mapping”, Nat Biotechnol., vol. 22(1), Jan. 2004, pp. 93-97. |
Gopee et al., “Migration of Intradermally Injected Quantum Dots to Sentinel Organs in Mice”, Toxicological Sciences, vol. 98(1), Apr. 2007, pp. 249-297. |
Soltesz et al., “Intraoperative Sentinel Lymph Node Mapping of the Lung Using Near-Infrared Fluorescent Quantum Dots”, Ann thorac. Surg., vol. 79(1), Jan. 2005, pp. 269-277 (reproduced from NUH Public Access). |
Peleg et al., “Implementing Metal Detector Technology and a Navidation System in the Removal of Shrapnel”, Computer Aided Surgery, vol. 14, No. 103, Dec. 2009, pp. 63-68. |
Conners, “Diagnostic Uses of Metal Detectors: A Review”, Int. J. Clin. Pract., vol. 59(8), Aug. 2005, Blackwell Publishing, pp. 946-949. |
Cash et al., “Breast Cancers: Noninvasive Method of Preoperative Localization with Three-Dimensional US and Surface Contour Mapping”, Published online before print Sep. 21, 2007, doi: 10.1148/radiol.2452060906, Nov. 2007, Radiology, 245, pp. 556-566, (downloaded on Sep. 28, 2011 from http://radiology.rsna.org/content/245/2/556.full). |
Peleg et al., “Integration of Computer-Aided Navidation and Metal Detector Technology in the Removal of Shrapnel in Terror Attacks Casualties”, 7th Int. Conf. Computer-Aided Orthopaedic Surgery, Heidelberg, Germany, 2007, pp. 57-60. |
Gunasekera et al., “Imaging Applications of Nanotechnolgy in Cancer”, Targeted Oncology, vol. 4, 2009, pp. 169-181. |
PCT International Search Report and PCT Written Opinion of International Searching Authority for International Patent Application No. PCT/GB2010/002233, mailed Mar. 16, 2011, (14 pages). |
Williamson S.J. et al.; “Biomagnetism”; Journal of Magnetism and Magnetic Materials; XP000574230; 1981; vol. 22; pp. 129-201. |
Harnan, S.E. et al.; “Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis”; EJSO The Journal of Cancer Surgery; 2011; vol. 37, pp. 928-936. |
Material Safety Data Sheet; Revision Date Mar. 5, 2007; Retrieved from the internet: URL:https://tools.lifetechnologies.com/content/sfs/msds/2007/11361DVIAL1:MTR-NAIV_EN.pdf [retrieved on Jun. 10, 2014]; abstract; (6 pages). |
Tsay, Tzong T. et al.; “Deep Cervical Lymph Flow Following the Infusion of Mannitol in Rabbits”; Life Sciences; 1997; vol. 61, No. 19; pp. 1929-1934. |
PCT International Search Report and Written Opinion from PCT Application No. PCT/GB2013/051885 dated Nov. 14, 2013, 18 pages. |
Jakub et al., Current status of radioactive seed for localization of non palpable breast lesions, The American Journal of Surgery, Apr. 2010, vol. 199 No. 4, pp. 522-528. |
Meenach, “Synthesis and Characterization of Magnetic Hydrogel Nanocomposites for Cancer Therapy Applications,” 2010, Doctoral Dissertations, Paper 108, http://uknowledge.uky.edu/gradschool_diss/108. |
Postma et al., “Localization of nonpalpable breast lesions,” Expert Rev. Anticancer Ther., 2011, vol. 11, No. 8, pp. 1295-1302. |
Communication from corresponding EP Application No. 16728722.6 dated Apr. 29, 2019. |
Groessinger et al., “Frequency Dependence of the Coercivity of Soft magnetic Materials”, IEEE Transactions on Magnetics 48(4):1473-1476 (2012). |
Drake; “Notes on Magnetic Measurements”; National Physical Laboratory Report; CETM; Nov. 1995; (25 pages). |
Fiorillo; “Measurements of Magnetic Material”; Metrologia; 47; (2010); S114-S142; (29 pages). |
BS EN 60404-7; “Method of measurement of the coercivity of magnetic materials in an open magnetic circuit”; BSI Group Headquarters; Part 7; (2016); (19 pages). |
BS EN 10330:2015; “Magnetic materials—Method of measurement of the coercivity of magnetic materials in an open magnetic circuit”; BSI Standards Publication; (2015); (16 pages). |
Number | Date | Country | |
---|---|---|---|
20230320811 A1 | Oct 2023 | US |
Number | Date | Country | |
---|---|---|---|
62170768 | Jun 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16688318 | Nov 2019 | US |
Child | 17988146 | US | |
Parent | 15172187 | Jun 2016 | US |
Child | 16688318 | US |